67 related articles for article (PubMed ID: 16820883)
1. Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells.
Quick QA; Gewirtz DA
Int J Oncol; 2006 Aug; 29(2):407-12. PubMed ID: 16820883
[TBL] [Abstract][Full Text] [Related]
2. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Holdhoff M; Kreuzer KA; Appelt C; Scholz R; Na IK; Hildebrandt B; Riess H; Jordan A; Schmidt CA; Van Etten RA; Dörken B; le Coutre P
Blood Cells Mol Dis; 2005; 34(2):181-5. PubMed ID: 15727903
[TBL] [Abstract][Full Text] [Related]
5. Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
Ranza E; Bertolotti A; Facoetti A; Mariotti L; Pasi F; Ottolenghi A; Nano R
Anticancer Res; 2009 Nov; 29(11):4575-8. PubMed ID: 20032406
[TBL] [Abstract][Full Text] [Related]
6. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
7. High-dose acetaminophen inhibits the lethal effect of doxorubicin in HepG2 cells: the role of P-glycoprotein and mitogen-activated protein kinase p44/42 pathway.
Manov I; Bashenko Y; Eliaz-Wolkowicz A; Mizrahi M; Liran O; Iancu TC
J Pharmacol Exp Ther; 2007 Sep; 322(3):1013-22. PubMed ID: 17526808
[TBL] [Abstract][Full Text] [Related]
8. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA.
Le Jeune N; Dubois F; Bin V; Perek N
Eur J Cancer; 2006 May; 42(8):1004-13. PubMed ID: 16564690
[TBL] [Abstract][Full Text] [Related]
10. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
11. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
12. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
[TBL] [Abstract][Full Text] [Related]
13. Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation.
Takada Y; Ichikawa H; Pataer A; Swisher S; Aggarwal BB
Oncogene; 2007 Feb; 26(8):1201-12. PubMed ID: 16924232
[TBL] [Abstract][Full Text] [Related]
14. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
Brama M; Basciani S; Cherubini S; Mariani S; Migliaccio S; Arizzi M; Rosano G; Spera G; Gnessi L
Endocr Relat Cancer; 2007 Mar; 14(1):61-72. PubMed ID: 17395975
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori and mitogen-activated protein kinases regulate the cell cycle, proliferation and apoptosis in gastric epithelial cells.
Ding SZ; Smith MF; Goldberg JB
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e67-78. PubMed ID: 18702686
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
17. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
18. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
Liu Y; Perdreau SA; Chatterjee P; Wang L; Kuan SF; Duensing A
Cancer Res; 2008 Nov; 68(21):9015-23. PubMed ID: 18974147
[TBL] [Abstract][Full Text] [Related]
20. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.
Rivas MA; Carnevale RP; Proietti CJ; Rosemblit C; Beguelin W; Salatino M; Charreau EH; Frahm I; Sapia S; Brouckaert P; Elizalde PV; Schillaci R
Exp Cell Res; 2008 Feb; 314(3):509-29. PubMed ID: 18061162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
